More than ever, biopharmaceutical companies are under pressure to deliver products that are not only effective and safe, but are also cost-effective and deliver value to patients.
As the healthcare industry continues to transition toward value-based payment models, payers and providers are insisting manufacturers link prices to results. Companies must now meet the demands of an increasing number of value-assessment frameworks and produce evidence that allows them to distinguish their products from competitors. At the same time, breakthroughs in precision medicine offer unprecedented data and tools to accelerate the discovery and development of new drugs.
To remain competitive, companies are looking for innovative approaches that drive the creation of new therapies and demonstrate the value of late-stage clinical and newly marketed products.
GNS solutions, services, and platforms provide companies with the ability to:
- Identify new biological targets and validate mechanisms faster
- Discover biomarkers to stratify patients
- Accelerate the development of novel drugs and companion diagnostics
- Develop personalized treatment options
- Maximize the value of your therapies in the framework of payers, providers, and patients